{"slideshow_credits": null, "snippet": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals....", "abstract": "Medivation, maker of prostate cancer medication Xtandi, agrees to $14 billion acquisition bid from Pfizer; deal is part of Pfizer's push into oncology drugs, which appear to be resistant to cost-cutting efforts by insurers; Xtandi sales are expected to reach $4 billion annually. ", "section_name": "Business Day", "print_page": "1", "document_type": "article", "byline": {"person": [{"firstname": "Andrew", "role": "reported", "lastname": "POLLACK", "rank": 1, "organization": ""}, {"firstname": "Leslie", "role": "reported", "lastname": "PICKER", "rank": 2, "organization": ""}], "original": "By ANDREW POLLACK and LESLIE PICKER"}, "web_url": "http://www.nytimes.com/2016/08/23/business/dealbook/medivation-pfizer-14-billion-deal.html", "lead_paragraph": "The frenzy over Medivation, which makes treatments for prostate and breast cancers, shows what pharmaceutical companies are willing to pay for oncology deals.", "headline": {"main": "Pfizer to Buy Cancer Drug Maker in $14 Billion Deal", "print_headline": "Pfizer Pays $14 Billion to Expand in Oncology"}, "_id": "57baea0b95d0e021d7981f10", "word_count": "1244", "multimedia": [{"height": 126, "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 366, "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg", "legacy": {"xlarge": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "366"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/08/23/business/23DB-MEDIVATION2/23DB-MEDIVATION-1471896501249-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2016-08-23T04:00:00+0000", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "organizations", "value": "Medivation Inc", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "Pfizer Inc", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}